Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as eva...
Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
About this item
Full title
Author / Creator
Publisher
Melbourne: Wiley Publishing Asia Pty Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: Wiley Publishing Asia Pty Ltd
Subjects
More information
Scope and Contents
Contents
Background and Aim
This retrospective study investigated the effect of 48‐week pemafibrate therapy in non‐alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase (FAST) score.
Methods
A total of 31 NAFLD patients who were treated with pemafibrate in Gunma Saiseikai Maebashi...
Alternative Titles
Full title
Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0c8a1c9125ca4b23908910c910d556d7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0c8a1c9125ca4b23908910c910d556d7
Other Identifiers
ISSN
2397-9070
E-ISSN
2397-9070
DOI
10.1002/jgh3.12650
